Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAME-PD: Physical Therapy, Atomoxetine and Methylphenidate to Enhance Gait and Balance in Parkinson's Disease
NCT02879136Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of methylphenidate and atomoxetine in Parkinson's disease (PD) (3 arms). Primary endpoint: Balance Evaluation at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
methylphenidateatomoxetine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02879136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879136.